Trypanosoma cruzi defined antigens in the serological evaluation of an outbreak of acute Chagas disease in Brazil (Catolé do Rocha, Paraíba)
Open Access
- 1 February 1996
- journal article
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 91 (1) , 87-93
Abstract
Immunoglobulin G and M humoral response to recombinant protein B13 and glycoconjugate LPPG Trypanosoma cruzi defined antigens was evaluated by ELISA in 18 patients in the acute phase of Chagas disease, who were contaminated on the same occasion. LPPG showed 100% positivity detecting both IgM and IgG antibodies, while positivity of 55-65% was observed for B13. An epimastigote alkaline extract (EPI) also showed high sensitivity for acute IgM (100%) and IgG (90%) antibodies. However LPPG had better discriminatory reactivity since with EPI two patients showed negative IgG and several other sera presented OD values for IgG and IgM antibodies very close to the cutoff. Thus, it is suggested that detection of IgM antibodies by LPPG may be used for diagnosis of the acute phase of Chagas disease. An intense decline of IgG and IgM antibodies to the three antigens was observed in response to anti-T. cruzi chemotherapy in all acute phase patients. After treatment, six (30%) individuals maintained IgG positivity to EPI, LPPG, and B13 with lower reactivity than that measured at the acute phase. For comparison, serology of a group of 22 patients in the chronic phase of Chagas disease and also submitted to chemotherapy was determined. Positive IgM antibodies to EPI, LPPG and B13 were detected in only 5-9% cases. In all chronic-phase patients IgG antibodies highly reactive to the three antigens were present and no significant decrease resulted after benznidazole administration. These observations reinforce previous reports that treatment in the acute phase may reduce or eliminate the parasite.Keywords
This publication has 17 references indexed in Scilit:
- Alkaline soluble Trypanosoma cruzi epimastigote antigen (ASEA) applied to dot-ELISARevista do Instituto de Medicina Tropical de São Paulo, 1994
- Galactofuranose-containing glycoconjugates of epimastigote and trypomastigote forms of Trypanosoma cruziMolecular and Biochemical Parasitology, 1993
- Possible oral transmission of acute Chagas' disease in BrazilRevista do Instituto de Medicina Tropical de São Paulo, 1991
- Direct lysis of Trypanosoma cruzi: a novel effector mechanism of protection mediated by human anti‐gal antibodiesParasite Immunology, 1991
- Structural features of the lipopeptidophosphoglycan from Trypanosoma cruzi common with the glycophosphatidylinositol anchorsEuropean Journal of Biochemistry, 1990
- Chagas' disease: IgA, IgM and IgG antibodies to T. cruzi amastigote, trypomastigote and epimastigote antigens in acute and in different chronic forms of the diseaseRevista do Instituto de Medicina Tropical de São Paulo, 1990
- Cross‐Reactive Polysaccharides from Trypanosoma cruzi and Fungi (Especially Dactylium dendroides)1The Journal of Protozoology, 1986
- Confidence intervals rather than P values: estimation rather than hypothesis testing.BMJ, 1986
- Effect of specific chemotherapy on the levels of lytic antibodies in Chagas's diseaseTransactions of the Royal Society of Tropical Medicine and Hygiene, 1982
- Evidence for the presence of D‐galactofuranose in the lipopeptidophosphoglycan from Trypanosoma cruziFEBS Letters, 1980